Matthew W Kalnik

Antidote Therapeutics, Inc.

NIH Rank #1036
  • Program Leader
  • Top 10% Funded
  • Early Career

NIH Funding · FY2024

Total Funding
$5.2M
Fiscal year 2024
Grants Awarded
1
Active NIH grants
National Rank
#1,036
Among 57,894 PIs
First NIH Award
2024
Year of first funding

Funding & rank history

NIH funding totals and national rank by fiscal year.

Single fiscal year on record (FY2024): $5.2M across 1 grant · National rank #1036.

Top grants by award amount

Matthew W Kalnik's NIH grant portfolio, ranked by award amount.

  • 5U01DA058547-02U01
    IND-enabling Studies in Support of First in Human Safety Studies of a Novel Anti-Nicotine Human Monoclonal Antibody
    $5.2M
    award amount

Affiliation

Institutions that have administered grants for Matthew W Kalnik.

Affiliated with Antidote Therapeutics, Inc. (MD).

Career milestones

Key NIH funding milestones over time.

  1. 2024
    First NIH Award
    Antidote Therapeutics, Inc.
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    $2M Cumulative Funding
  5. 2024
    $5M Cumulative Funding
  6. 2024
    Entered Top 50% Nationally
    Ranked #1036
  7. 2024
    Entered Top 25% Nationally
    Ranked #1036
  8. 2024
    Entered Top 10% Nationally
    Ranked #1036